Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. JAMA Oncol 2023 Feb 01;9(2):275-276
Date
12/02/2022Pubmed ID
36454556DOI
10.1001/jamaoncol.2022.6138Scopus ID
2-s2.0-85148307010 (requires institutional sign-in at Scopus site) 1 CitationAuthor List
Hall WA, Evans DB, Tsai SAuthors
Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of WisconsinWilliam Adrian Hall MD Professor in the Radiation Oncology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Antineoplastic Combined Chemotherapy ProtocolsFluorouracil
Humans
Neoadjuvant Therapy
Pancreatic Neoplasms